CNS Pharmaceuticals, Inc. (CNSP)
- Previous Close
0.2095 - Open
0.2050 - Bid --
- Ask --
- Day's Range
0.1999 - 0.2190 - 52 Week Range
0.1900 - 2.9800 - Volume
528,071 - Avg. Volume
362,663 - Market Cap (intraday)
2.428M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-7.8200 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
www.cnspharma.comRecent News: CNSP
Performance Overview: CNSP
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNSP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNSP
Valuation Measures
Market Cap
2.48M
Enterprise Value
1.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-240.80%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.46M
Diluted EPS (ttm)
-7.8200
Balance Sheet and Cash Flow
Total Cash (mrq)
815.23k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.61M